NovoCure (FRA:038) Dividends per Share : €0.00 (TTM As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is NovoCure Dividends per Share?

NovoCure's dividends per share for the three months ended in Mar. 2025 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2025 was 0.00. As of today, NovoCure's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

NovoCure Dividends per Share Historical Data

The historical data trend for NovoCure's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Dividends per Share Chart

NovoCure Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividends per Share

Get a 7-Day Free Trial

NovoCure Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of NovoCure's Dividends per Share

For the Medical Devices subindustry, NovoCure's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovoCure's Dividend Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where NovoCure's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

NovoCure Dividends per Share Calculation

Dividends paid to per common share.

NovoCure (FRA:038) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

NovoCure's Dividend Payout Ratio for the quarter that ended in Mar. 2025 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2025 )	/	EPS without NRI (Q: Mar. 2025 )
	=	0	/	-0.287
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

NovoCure Dividends per Share Related Terms

Thank you for viewing the detailed overview of NovoCure's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (FRA:038) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

NVCR:USA

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Headlines

No Headlines